August 3, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Washington, D.C. 20549
Re: Response to Comment Letter, dated July 20, 2022
Form 10-K for the Year Ended December 31, 2021
File No. 000-56194
Dear Sir:
We have received your comment letter dated July 20, 2022 and are providing the following response to support the accounting treatment of the License Right, as disclosed in the 10-K for the Year Ended December 31, 2021.
We have expanded the disclosure in Coeptis Therapeutics, Inc.’s Quarterly Report for the period ended June 30, 2022, filed August 2, 2022, specifically in Note 3-License Right, regarding the Co-Development Options to address that significant judgements were made and determined that the options have alternative future use and were recorded as assets pursuant to ASC 730-10-25-2.
We thank the Staff for its review and comments. We are available for a call or further correspondence should you have any questions or require additional information.
Sincerely, | |
/s/ Christine Sheehy | |
Chief Financial Officer |